Figure 5
From: The green tea catechin EGCG provides proof-of-concept for a pan-coronavirus attachment inhibitor
EGCG competes for SARS-CoV-2 heparin binding. (a) VSV-SARS-CoV-2 virions (1 × 105 pfu) were pre-treated with 20 μg/mL heparin or mock and loaded onto a heparin column. After washing, still bound virions were then eluted with 2 M NaCl. Virions in flow through were quantified by viral RNA to determine percentage of bound virions before elution. (b) Alternatively, virions were loaded, and after washing, were eluted with 0.5 mg/mL heparin, EGCG, or NANA. Mean values with standard error of the mean of three independent experiments each with qPCR triplicates are plotted. Statistical significance was assessed by Welch’s t test (ns, not significant, *p < 0.05, ***p < 0.001, ****p < 0.0001).
